PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
AIDS. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
PMCID: PMC2921849
NIHMSID: NIHMS202926

Increased Aldosterone Among HIV-Infected Women with Visceral Fat Accumulation

Janet Lo, M.D., M.MSc., Sara E. Dolan Looby, Ph.D., ANP, Jeffrey Wei, Gail K. Adler, M..D., Ph.D., and Steven K. Grinspoon, M.D.

Abstract

Increased aldosterone has been associated with obesity and the metabolic syndrome in non HIV-infected patients, but aldosterone has not been investigated among HIV-infected patients with increased visceral adipose tissue (VAT). 24-hour urine aldosterone was assessed among age and BMI-matched HIV-infected women with increased VAT, HIV-infected women without increased VAT and healthy controls. 24-hour urine aldosterone was higher in HIV-infected women with increased VAT and was associated with systolic blood pressure, VAT, and hemoglobin A1c. Increased aldosterone may contribute to the detrimental effects of excess visceral adiposity on blood pressure and glucose homeostasis among HIV patients.

Keywords: Aldosterone, Lipodystrophy, HIV, Visceral Fat

Increased aldosterone levels have been associated with the metabolic syndrome [13] and visceral adiposity [4] in non HIV-infected patients. Whether aldosterone is increased in association with abdominal adiposity and relates to metabolic dysregulation in HIV-infected patients is unknown. In order to begin to assess whether increased aldosterone may contribute in part to the metabolic derangements among HIV-infected patients with central fat accumulation, we investigated the relationship of aldosterone to measures of visceral fat and metabolic indices in HIV-infected women and healthy control women.

We hypothesized that aldosterone would be increased among HIV-infected women with excess visceral fat accumulation. We therefore selected three groups of patients from a prior study [5], in whom samples of 24 hour urine collections were available, for measurement of 24-hour urine aldosterone levels: 1) a control group (n=20) of non HIV-infected patients, 2) an HIV group with VAT similar to the control group (n=21), and 3) an HIV group with VAT that was increased compared to the control group (n=22), to assess the relationship of urinary aldosterone and HIV per se vs. increased VAT. The groups were chosen prior to the performance of the aldosterone assay, and were matched for age and BMI to the control group, but with distinct patterns of VAT in the two HIV groups (normal and increased). Aldosterone could not be run in the entire group of original patients due to availability of urine samples. The study was approved by the Massachusetts General Hospital IRB and subjects provided written informed consent. Biochemical testing was performed following an overnight fast.

Urine aldosterone concentration was measured using a radioimmunoassay (Diagnostic Products Corporation) and multiplied by the total volume over 24 hours. Fisher’s least significant difference test was used and if statistical significance was met for the three group comparisons by ANOVA, further pair-wise comparisons were performed using Student’s T-test. Univariate relationships with aldosterone were assessed using Pearson correlation coefficient. Multivariate linear regression modeling was used to examine the relationship of aldosterone to visceral fat and glucose parameters, adjusting for relevant covariates that might influence aldosterone, including also race and use of anti-hypertensive medications.

Demographics, body composition, metabolic parameters and medication use are shown in Table 1. Age and BMI did not differ between the groups. HIV-infected patients with increased VAT demonstrated increased 24-hour urinary aldosterone (Table 1). Among HIV-infected participants, rates of use of PI’s, NRTI’s, NNRTI’s and immune parameters were similar between participants with and without increased VAT. Antihypertensive use was not different between the groups and none of the participants were taking mineralocorticoid receptor antagonists. Serum and urinary creatinine, urinary volume, dietary sodium and potassium intake were similar in all three groups. Similar results were seen when the 24-hour aldosterone levels were normalized for urine creatinine. Urine free cortisol levels were not increased among those with increased VAT. 24-hour urine aldosterone was not significantly different between HIV patients with NCEP-defined metabolic syndrome (26.7 ± 20.6 nmol/24h) vs. HIV patients without the metabolic syndrome (19.7 ± 22.1 nmol/24h) (p=0.38). Thirty-four patients were on current antiretroviral therapy (ART) and 9 patients were not. Compared to the non HIV-infected control subjects, urinary aldosterone was similar in the HIV group not on ART, but tended to be increased among the HIV group on ART (13.4 ± 12.5 for non HIV-infected control, 13.0 ± 8.5 for HIV not on ART, and 23.3 ± 22.5 nmol/24h (mean ± SD) for HIV on ART)(p=0.11).

Table 1
Clinical Characteristics of Study Participants

In HIV-infected participants, 24-hour urine aldosterone was significantly associated with systolic blood pressure (r =0.36, p=0.01), BMI (r=0.37, p=0.01), total body fat (r=0.31, p= 0.04), VAT (r=0.34, p=0.03), and hemoglobin A1c (r=0.50, p=0.001), but not with subcutaneous adipose tissue (SAT) (r=0.19, p=0.23) (Table 2A). By multivariate regression analyses, in a model including age, race, BMI, PI, NRTI, NNRTI use, VAT, hemoglobin A1c, 24-hour urine sodium and anti-hypertension medications, VAT (β=0.14 nmol/24h per cm2 change in VAT, p= 0.01) and hemoglobin A1c (β=17.28 nmol/24h per % change in hemoglobin A1c, p= 0.0001) remained significantly related to 24-hour aldosterone, among the HIV-infected patients. Overall model r2 was 0.79 (Table 2B).

In this study, we demonstrate increased 24-hour urine aldosterone in HIV-infected women with increased visceral fat accumulation, compared to age and BMI-matched healthy controls and HIV-infected subjects without visceral fat accumulation. To our knowledge this is the first report to suggest that aldosterone may be increased among the subgroup of HIV-infected patients who experience increased visceral fat accumulation and to suggest an independent relationship between increased aldosterone and hemoglobin A1c, an index of overall glucose homeostasis.

Our findings relating aldosterone to adiposity are consistent with prior studies in non-HIV populations and extend these results for the first time to a human model with acquired visceral adiposity that differs from a model of more generalized obesity. Rossi et al. found plasma aldosterone correlated with BMI in overweight-obese patients with primary hypertension and Bentley-Lewis et al. showed 24-hour urine aldosterone correlated with BMI in normotensive overweight and obese participants [6, 7]. To our knowledge, there is only one prior study relating aldosterone to VAT in humans, demonstrating that plasma aldosterone correlated with VAT in non HIV-infected, normotensive women[4].

Among HIV-infected patients, both loss of subcutaneous fat and increases in visceral fat have been found, though these changes may not be linked physiologically and may result from different mechanisms [8]. In a recent study among the Swiss HIV Cohort, approximately 22% were shown to have clinically significant abdominal lipohypertrophy[9], and treatment strategies to treat the metabolic abnormalities among these patients are needed. Our data demonstrate that 24-hour urine aldosterone is associated with VAT, but not with SAT in HIV-infected women. Urinary aldosterone measures were used to obtain an integrated measure of aldosterone throughout the day, as in prior studies relating aldosterone to adiposity[6, 10]. Dietary sodium, urinary creatinine, urinary volume and serum creatinine were equivalent in all three groups. Fat, protein and carbohydrate intake were also similar among the groups.

We found a strong association of aldosterone with hemoglobin A1c, independent of BMI or visceral adiposity. Other studies have found correlations between aldosterone and markers of insulin resistance in overweight and obese patients without HIV [4, 6, 11]. We did not find an association of aldosterone with HOMA-IR or other measures of short-term glucose homeostasis; however, this may be due to differences in our study population. For example, the mean BMI in our study (25.6 kg/m2) was not as high as in the other studies[4, 6, 11]. Prior in vitro studies suggest that aldosterone can negatively affect insulin action [12] and animal studies have shown that mineralocorticoid blockade can improve indices of insulin resistance [10]. Further studies are necessary to determine if increased aldosterone mediates, in part, dysregulation of the glucose axis in HIV-infected patients with increased visceral adiposity and the effects of mineralocorticoid blockade on glucose and other metabolic parameters in these patients.

The study was conducted in women only and thus the results may not be generalizable to men. Future studies in larger number of HIV patients, including men, are needed to confirm these findings. Moreover, the cross-sectional nature of our study does not allow us to answer questions of causation, for example as to whether altered adipogenesis contributes to increased aldosterone, as suggested in prior in vitro studies[13].

Our data may have potential cardiovascular and metabolic implications for the subgroup of HIV-infected patients with increased visceral fat accumulation[14], in whom increased aldosterone could also contribute to cardiovascular risk through effects on blood pressure, renal function and glucose homeostasis. Moreover, manipulation of the aldosterone axis could potentially be useful as a novel treatment strategy among HIV patients with increased visceral fat accumulation. These data suggest the need for future studies to confirm the relationship of aldosterone and visceral adiposity in HIV-infected patients and to investigate the effects of mineralocorticoid receptor blockade in HIV patients with excess visceral adiposity. Further studies are also needed to determine whether increased aldosterone is related in part to ART, immune, viral or host factors among HIV-infected patients with increased visceral fat accumulation.

ACKNOWLEDGMENTS

We wish to thank the staff of the General Clinical Research Centers at MGH and MIT, and all of the participants who volunteered in this study.

Supported by NIH K23 HL092792, NIH RO1 DK 59535, NIH K24 DK064545, and NIH M01 RR01066-25S1

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

REFERENCES

1. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984–992. [PubMed]
2. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776–783. [PMC free article] [PubMed]
3. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88–90. [PubMed]
4. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7:355–362. [PubMed]
5. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39:44–54. [PubMed]
6. Bentley-Lewis R, Adler GK, Perlstein T, et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab. 2007;92:4472–4475. [PubMed]
7. Rossi GP, Belfiore A, Bernini G, et al. Body Mass Index Predicts Plasma Aldosterone Concentrations in Overweight-Obese Primary Hypertensive Patients 10.1210/jc.2008-0251. J Clin Endocrinol Metab. 2008;93:2566–2571. [PubMed]
8. Tien P. FRAM. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42:562–571. [PMC free article] [PubMed]
9. Nguyen A, Calmy A, Schiffer V, et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006. HIV Med. 2008;9:142–150. [PubMed]
10. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253–2261. [PMC free article] [PubMed]
11. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30:2349–2354. [PubMed]
12. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology. 2009;150:1662–1669. [PubMed]
13. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–14216. [PubMed]
14. Martinez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis. 2009;22:28–34. [PubMed]